biostudies-literatureUnknownSchuster NMAcademic Senate, University of California, RiversideNCATS NIH HHSNCCIH NIH HHSNINDS NIH HHSNational Institutes of HealthMigraine Research FoundationNIH HHSAcademic Senate, University of California, San Diego<h4>Objective</h4>To assess the efficacy of cannabis for the treatment of acute migraine.<h4>Background</h4>Preclinical and retrospective studies suggest cannabinoids may be effective in migraine treatment. However, there have been no randomized clinical trials examining the efficacy of cannabinoids for acute migraine.<h4>Methods</h4>In this randomized, double-blind, placebo-controlled, crossover trial, adults with migraine treated up to four separate migraine attacks, one each with vaporized (1) 6% Δ9-tetrahydrocannabinol (THC) (THC-dominant), (2) 11% cannabidiol (CBD) (CBD-dominant), (3) 6% THC + 11% CBD, and (4) placebo cannabis flower in a randomized order. Washout period between treated migraine attacks was ≥1 week. The primary endpoint was pain relief, and secondary endpoints were paHeadachehttps://www.ebi.ac.uk/biostudies/studies/S-EPMC12872409biostudies-literatureVaporized cannabis versus placebo for acute migraine: A randomized, double-blind, placebo-controlled crossover trial.PMC12872409UL1TR001442UL1 TR001442R00 AT009466UL1 TR000100U24 NS115714OT2 NS122680Schuster NMLiu LWallace MSMarcotte TDSexton MBuse DCLee EfalseVaporized cannabis versus placebo for acute migraine: A randomized, double-blind, placebo-controlled crossover trial.<h4>Objective</h4>To assess the efficacy of cannabis for the treatment of acute migraine.<h4>Background</h4>Preclinical and retrospective studies suggest cannabinoids may be effective in migraine treatment. However, there have been no randomized clinical trials examining the efficacy of cannabinoids for acute migraine.<h4>Methods</h4>In this randomized, double-blind, placebo-controlled, crossover trial, adults with migraine treated up to four separate migraine attacks, one each with vaporized (1) 6% Δ9-tetrahydrocannabinol (THC) (THC-dominant), (2) 11% cannabidiol (CBD) (CBD-dominant), (3) 6% THC + 11% CBD, and (4) placebo cannabis flower in a randomized order. Washout period between treated migraine attacks was ≥1 week. The primary endpoint was pain relief, and secondary endpoints were pa2025-01-01T00:00:00Z2025 Dec2026-07-15T13:57:17.125Z2026-07-05T03:12:22.359ZS-EPMC128724094146948810.1111/head.70025